Xencor, Inc.

Genentech, Inc.

Michael Hedvat

John R Desjarlais

Gregory L Moore

Matthew J Bernett

Christine Bonzon

Alex Nisthal

Juan Diaz

Rumana Rashid

Rajat Varma

Matthew Adam Dragovich

Veronica Gusti Zeng

Umesh Muchhal

Adam Zwolak

Suzanne Schubbert

Fei Shen

Joseph Erhardt

Fouad Moussa

Pankaj Seth

Theresa McDevitt

Ke Liu

Nargess Hassanzadeh-Kiabi

Yoon Kyung Kim

Christine Huang

Patrick Holder

Umesh S Muchhal

Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.

Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

Provided herein are novel anti-CD28×anti-B7H3 (also referred to as 'αCD28×αB7H3') heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

Anti-CD28 compositions

The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.

Targeted IL-12 heterodimeric Fc-fusion proteins

Provided herein are novel anti-CD28&#xd7;anti-B7H3 (also referred to as '&#x3b1;CD28&#xd7;&#x3b1;B7H3') heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject &#x3b1;CD28&#xd7;&#x3b1;B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

The present invention is directed to heterodimeric anti-LAG-3&#xd7;anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

Bispecific checkpoint inhibitor antibodies

The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R&#x3b1;-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R&#x3b1;-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R&#x3b1;-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.

PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof

The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

Growing community of inventors

Encino, CA, United States of America

Michael Hedvat